Want to see HK:1789 full AI Analyst Report?
1789 Stock Chart & Stats
HK$5.91
-HK$0.05(-1.15%)
At close: 4:00 PM EST
HK$5.91
-HK$0.05(-1.15%)
Day’s Range― - ―
52-Week RangeHK$4.75 - HK$7.15
Previous CloseN/A
Volume3.85M
Average Volume (3M)4.30M
Market Cap
HK$6.19B
Enterprise ValueHK$4.91K
Total Cash (Recent Filing)HK$1.47B
Total Debt (Recent Filing)HK$144.79M
Price to Earnings (P/E)15.8
Beta1.08
Next Earnings
Sep 02, 2026EPS Estimate
0.2Next Dividend Ex-DateN/A
Dividend Yield2.14%
Share Statistics
EPS (TTM)0.30
Shares Outstanding1,124,616,700
10 Day Avg. Volume3,969,892
30 Day Avg. Volume4,297,109
Financial Highlights & Ratios
PEG Ratio0.85
Price to Book (P/B)1.97
Price to Sales (P/S)3.87
P/FCF Ratio18.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.37
Revenue Forecast (FY)HK$1.65B
Bulls Say, Bears Say
Bulls Say
High ProfitabilitySustained high gross and operating margins point to strong product economics and pricing power in orthopaedic implants. This margin cushion supports reinvestment in R&D, funds incremental SG&A for commercial expansion, and preserves earnings through cost shocks, making profits durable even if volumes fluctuate.
Very Low LeverageAn exceptionally conservative balance sheet with minimal debt gives the company flexibility to fund capex, M&A, or R&D without heavy interest burden. Low leverage reduces solvency risk in downturns and preserves strategic optionality for longer-term investments in product development and hospital coverage.
Positive Revenue GrowthConsistent top-line expansion to 1.44B demonstrates steady demand and adoption of the company’s implant portfolio. Reliable revenue growth underpins scalable margins and supports continued investment in commercial reach and product development, reinforcing the business model over a multi-quarter horizon.
Bears Say
Cash-Flow VolatilityMaterial swings in operating cash flow and a negative free cash flow year indicate uneven working-capital and conversion dynamics. This volatility weakens the link between reported profits and cash available for investment or distributions, requiring conservative capital planning and increasing execution risk.
Moderate Cash ConversionEven with healthy net income, cash conversion below full coverage means earnings don't fully translate into cash. That limits the company’s ability to accelerate deleveraging, fund bolt-on investments, or raise shareholder returns without relying on variability in working capital or external financing.
Growth & Margin Normalization RiskHistorical volatility in revenue and a trend of margins normalizing from 2020 peaks suggest exposure to competitive pricing, tender cycles, or procedure mix shifts. Maintaining current margin levels may be challenging if market conditions or reimbursement dynamics deteriorate, pressuring medium-term profitability.
AK Medical Holdings Ltd. News
1789 FAQ
What was AK Medical Holdings Ltd.’s price range in the past 12 months?
AK Medical Holdings Ltd. lowest stock price was HK$4.75 and its highest was HK$7.15 in the past 12 months.
What is AK Medical Holdings Ltd.’s market cap?
AK Medical Holdings Ltd.’s market cap is HK$6.19B.
When is AK Medical Holdings Ltd.’s upcoming earnings report date?
AK Medical Holdings Ltd.’s upcoming earnings report date is Sep 02, 2026 which is in 29 days.
How were AK Medical Holdings Ltd.’s earnings last quarter?
AK Medical Holdings Ltd. released its earnings results on Mar 25, 2026. The company reported HK$0.186 earnings per share for the quarter, beating the consensus estimate of HK$0.174 by HK$0.012.
Is AK Medical Holdings Ltd. overvalued?
According to Wall Street analysts AK Medical Holdings Ltd.’s price is currently Overvalued.
Does AK Medical Holdings Ltd. pay dividends?
AK Medical Holdings Ltd. pays a Annually dividend of HK$0.118 which represents an annual dividend yield of 2.14%. See more information on AK Medical Holdings Ltd. dividends here
What is AK Medical Holdings Ltd.’s EPS estimate?
AK Medical Holdings Ltd.’s EPS estimate is 0.2.
How many shares outstanding does AK Medical Holdings Ltd. have?
AK Medical Holdings Ltd. has 1,124,616,700 shares outstanding.
What happened to AK Medical Holdings Ltd.’s price movement after its last earnings report?
AK Medical Holdings Ltd. reported an EPS of HK$0.186 in its last earnings report, beating expectations of HK$0.174. Following the earnings report the stock price went up 2.634%.
Which hedge fund is a major shareholder of AK Medical Holdings Ltd.?
Currently, no hedge funds are holding shares in HK:1789
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AK Medical Holdings Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
26.55%
12-Months-Change
Fundamentals
Return on Equity
2.14%
Trailing 12-Months
Asset Growth
14.93%
Trailing 12-Months
Company Description
AK Medical Holdings Ltd.
AK Medical Holdings Limited, an investment holding enterprise, specializes in the research, development, production, and worldwide commercialization of orthopedic joint implants and related medical devices under the AK Medical brand. Its comprehensive product offerings encompass conventional knee, hip, and spine replacement implants, as well as advanced 3D-printed solutions like hip implants, artificial vertebral bodies, and spinal interbody cages. The company further expands its operations by distributing orthopedic products from third-party manufacturers and by fabricating surgical instruments and medical irrigators. Its diverse client base spans distributors, hospitals, physicians, surgeons, and directly serves patients. Established in Beijing, People's Republic of China, in 2003, AK Medical Holdings Limited functions as a subsidiary of Ximalaya Limited.
Technical Analysis
MicroPort Scientific
―
LifeTech Scientific Corporation
―
MicroPort CardioFlow Medtech Corp.
―
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
―
Venus Medtech (Hangzhou), Inc. Class H
―